Intellia Therapeutics reports after the close on May 14 with more than a third of its free float sold short — a level that makes the lending market the most important context for tomorrow's print.
Short interest has accelerated sharply into the event. At 36.4% of the free float, it jumped 12% in a single week and now ranks in just the 6th percentile of the universe — meaning virtually no stock carries a heavier short burden. Yet the borrow market is telling a different story. Cost to borrow is cheap at 0.61% annualised, down 11% on the week, and borrow availability remains well above the lows touched at the 52-week peak in mid-April. Shorts are not paying a squeeze premium. The ORTEX short score of 75.9 confirms the aggregate pressure, but the absence of borrow stress suggests the bears are comfortable rather than cornered.
Options traders are not leaning defensively into the print at all. The put/call ratio is running at 0.31 — essentially flat to its 20-day average of 0.31 and near the lower half of its 52-week range — which points to no meaningful demand for downside protection. That is a notable disconnect from the aggressive short positioning: the shorts are leaning hard, but options desks are not hedging alongside them.
The analyst debate frames the divergence clearly. Bulls, led by Canaccord Genuity (which reiterated Buy even while trimming its target to $49 from $58 on May 12), point to the Phase 3 HAELO trial results for lonvosirtide — 97% of HAE patients attack-free — and collaborations with Regeneron and Novartis as validation of the CRISPR platform. Goldman Sachs, which maintains a Sell with a $9 target, represents the bearish case: competitive pressure in HAE, the need for further equity financing, and IP uncertainty. Morgan Stanley sits in the middle, raising its Equal-Weight target to $15 from $11, essentially endorsing the current price with no conviction on direction. The mean analyst target of $26.55 implies substantial upside from $13.99, but that average is dragged up by outlier bull targets; the bearish anchor at $9 and the neutral anchor at $12-$15 are closer to where the stock trades today.
ARK Investment Management is the largest outside holder at 10.2% of shares, and added 2.3 million shares as recently as April — a clear endorsement of the bull case. Vanguard and BlackRock have also been building positions. On the other side, the January insider cluster — the CEO, CFO, CTO and Chief Medical Officer all selling on the same day — carries a different signal, though the small scale of those trades (all low significance scores) limits the read-through.
The February earnings print produced a modest 2.7% one-day gain that faded to a 2% loss over five days, suggesting the market has consistently struggled to hold post-earnings rallies. Tomorrow's report will test whether the HAELO data is already priced into a stock trading at 36% short interest, or whether a clean quarter and regulatory progress can begin to close the gap between the current price and even the most conservative analyst targets.
See the live data behind this article on ORTEX.
Open NTLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
